Lv64
1897 积分 2023-12-03 加入
Implementing scientifically sound practices during drug development: An industry perspective from analytical development
1天前
求助中
Impurity qualification requirements for drug-linkers related impurities used to generate antibody-drug conjugates
8天前
已完结
Monitoring of the disulfide scrambled species by mixed-mode SEC-HPLC during the purification of a bispecific antibody
9天前
已完结
Rapid online buffer exchange for screening of proteins, protein complexes and cell lysates by native mass spectrometry
18天前
已完结
Linker Chemistry in Antibody–Drug Conjugates: Current Strategies, Clinical Pharmacokinetic Analyses, and Linker-Free Outlooks
19天前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
21天前
已完结
Risk-Based Approach for Analytical Comparability and Comparability Protocols
22天前
已完结
Inhibition of protein carbamylation in urea solution using ammonium-containing buffers
23天前
已完结
Strategies for the Identification of Cyclic Peptide Drugs and Their Impurities
23天前
已完结
Small Molecule–Degrader Conjugates: Evaluating the Structure–Activity Relationship of Linkers to Overcome In Vivo Barriers in PROTAC Delivery
1个月前
已完结
皖公网安备34019202002308
